Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal ModelsGlobeNewsWire • 10/18/23
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive DisorderGlobeNewsWire • 10/16/23
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress EuropeGlobeNewsWire • 10/11/23
Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family ConferenceGlobeNewsWire • 10/09/23
Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of PainGlobeNewsWire • 10/04/23
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina's Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress DisGlobeNewsWire • 09/27/23
Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023GlobeNewsWire • 09/21/23
Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache CongressGlobeNewsWire • 09/18/23
Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023GlobeNewsWire • 09/14/23
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and SmallpoxGlobeNewsWire • 08/21/23
Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy VolunteersGlobeNewsWire • 08/16/23
Tonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 08/10/23
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVIDGlobeNewsWire • 08/07/23
Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating DisorderGlobeNewsWire • 07/31/23
Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) TestGlobeNewsWire • 07/24/23
Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety DisorderGlobeNewsWire • 07/15/23
Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric ObesityGlobeNewsWire • 07/10/23
